BTIG Research Lowers Evolent Health (NYSE:EVH) Price Target to $8.00

Evolent Health (NYSE:EVH) had its price objective dropped by BTIG Research from $10.00 to $8.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the technology company’s stock. BTIG Research’s price objective would suggest a potential upside of 140.24% from the company’s current price.

A number of other research firms also recently issued reports on EVH. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a report on Monday, December 29th. Zacks Research raised shares of Evolent Health from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Stephens upgraded shares of Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price target for the company in a research note on Thursday, November 13th. BMO Capital Markets began coverage on shares of Evolent Health in a research note on Thursday, November 13th. They set an “outperform” rating and a $7.00 price objective on the stock. Finally, Citizens Jmp cut their price objective on shares of Evolent Health from $11.00 to $10.00 and set a “market outperform” rating on the stock in a report on Tuesday, January 6th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Evolent Health Price Performance

EVH stock opened at $3.33 on Wednesday. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.33 and a quick ratio of 1.33. Evolent Health has a 1 year low of $2.50 and a 1 year high of $12.06. The firm has a 50-day moving average of $3.50 and a 200 day moving average of $5.84. The company has a market cap of $371.63 million, a P/E ratio of -0.65 and a beta of 0.27.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, February 24th. The technology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Evolent Health had a positive return on equity of 1.30% and a negative net margin of 28.49%.The firm had revenue of $468.72 million for the quarter, compared to the consensus estimate of $468.48 million. During the same quarter in the prior year, the business earned ($0.02) EPS. The business’s revenue for the quarter was down 27.5% on a year-over-year basis. On average, sell-side analysts forecast that Evolent Health will post 0.08 EPS for the current year.

Hedge Funds Weigh In On Evolent Health

Hedge funds have recently added to or reduced their stakes in the company. Alpine Global Management LLC purchased a new stake in Evolent Health during the 4th quarter valued at $175,000. Aristides Capital LLC bought a new position in shares of Evolent Health during the fourth quarter valued at $195,000. Virtu Financial LLC bought a new position in shares of Evolent Health during the fourth quarter valued at $106,000. Invesco Ltd. boosted its position in shares of Evolent Health by 30.4% during the fourth quarter. Invesco Ltd. now owns 392,282 shares of the technology company’s stock valued at $1,569,000 after buying an additional 91,370 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in shares of Evolent Health during the fourth quarter valued at $109,000.

More Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.